Herbal Medicines: Traditional Herbal Registration

Size: px
Start display at page:

Download "Herbal Medicines: Traditional Herbal Registration"

Transcription

1 Herbal Medicines: Traditinal Herbal Registratin In the UK, cmpanies can nly sell herbal medicines with the apprpriate prduct licence, as fllws: A full marketing authrisatin based n the safety, quality and efficacy f the herbal prduct; r A traditinal herbal registratin based n the safety, quality and evidence f traditinal use f the herbal prduct. In this article, Dr Rsanna Cper explres traditinal herbal medicines and traditinal herbal registratins. Herbal Prducts Are they Medicines, Fd r Csmetics? Herbal prducts can be classified as medicines, fd r csmetics. The key is t assess yur herbal prducts t ensure that they are crrectly classified and therefre cmpliant under the law. Traditinal Herbal Medicinal Prducts Article 1 f Directive 2001/83/EC (as amended) defines a traditinal herbal medicinal prduct as a herbal medicinal prduct that fulfils the cnditins laid dwn in Article 16a(1). The cnditins laid dwn in Article 16a(1) are as fllws: 1. A simplified registratin prcedure (hereinafter traditinal- use registratin ) is hereby established fr herbal medicinal prducts which fulfil all f the fllwing criteria: (a) they have indicatins exclusively apprpriate t traditinal herbal medicinal prducts which, by virtue f their cmpsitin and purpse, are intended and designed fr use withut the supervisin f a medical practitiner fr diagnstic purpses r fr prescriptin r mnitring f treatment; (b) they are exclusively fr administratin in accrdance with a specified strength and pslgy; (c) they are an ral, external and/r inhalatin preparatin; (d) the perid f traditinal use as laid dwn in Article 16c(1)(c) has elapsed; (e) the data n the traditinal use f the medicinal prduct are sufficient; in particular the prduct prves nt t be harmful in the specified cnditins f 1 P a g e

2 use and the pharmaclgical effects r efficacy f the medicinal prduct are plausible n the basis f lng-standing use and experience. A herbal medicinal prduct is defined in Article 1 f Directive 2001/83/EC (as amended) as any medicinal prduct, exclusively cntaining as active ingredients ne r mre herbal substances r ne r mre herbal preparatins, r ne r mre such herbal substances in cmbinatin with ne r mre such herbal preparatins. Herbal substances are defined as all mainly whle, fragmented r cut plants, plant parts, algae, fungi, lichen in an unprcessed, usually dried, frm, but smetimes fresh. Certain exudates that have nt been subjected t a specific treatment are als cnsidered t be herbal substances. Herbal substances are precisely defined by the plant part used and the btanical name accrding t the binmial system (genus, species, variety and authr). Traditinal Herbal Registratin A Traditinal Herbal Registratin is available, rather than a Marketing Authrisatin, fr placing traditinal herbal medicinal prducts n the market r fr their distributin by way f whlesale dealing in the UK. Under Directive 2004/24/EC: Recital 4 - Having regard t the particular characteristics f these medicinal prducts, especially their lng traditin, it is desirable t prvide a special, simplified registratin prcedure fr certain traditinal medicinal prducts. Hwever, this simplified prcedure shuld be used nly where n marketing authrisatin can be btained pursuant t Directive 2001/83/EC, in particular because f a lack f sufficient scientific literature demnstrating a wellestablished medicinal use with recgnised efficacy and an acceptable level f safety. It shuld likewise nt apply t hmepathic medicinal prducts eligible fr marketing authrisatin r fr registratin under Directive 2001/83/EC. (5) The lng traditin f the medicinal prduct makes it pssible t reduce the need fr clinical trials, in s far as the efficacy f the medicinal prduct is plausible n the basis f lng-standing use and experience. Pre-clinical tests d nt seem necessary, where the medicinal prduct n the basis f the infrmatin n its traditinal use prves nt t be harmful in specified cnditins f use. Hwever, even a lng traditin des nt exclude the pssibility that there may be cncerns with regard t the prduct's safety, and therefre the cmpetent authrities shuld be entitled t ask fr all data necessary fr assessing the safety. The quality aspect f the medicinal prduct is independent f its traditinal use s that n dergatin shuld be made with regard t the necessary physic-chemical, bilgical and micrbilgical tests. Prducts shuld cmply with quality standards in relevant Eurpean Pharmacpeia mngraphs r thse in the pharmacpeia f a Member State. 2 P a g e

3 (6) The vast majrity f medicinal prducts with a sufficiently lng and cherent traditin are based n herbal substances. It therefre seems apprpriate t limit the scpe f the simplified registratin in a first step t traditinal herbal medicinal prducts. (7) The simplified registratin shuld be acceptable nly where the herbal medicinal prduct may rely n a sufficiently lng medicinal use in the Cmmunity. Medicinal use utside the Cmmunity shuld be taken int accunt nly if the medicinal prduct has been used within the Cmmunity fr a certain time. Where there is limited evidence f use within the Cmmunity, it is necessary t assess carefully the validity and relevance f use utside the Cmmunity. (8) With the bjective f further facilitating the registratin f certain traditinal herbal medicinal prducts and f further enhancing harmnisatin, there shuld be the pssibility f establishing a Cmmunity list f herbal substances that fulfill certain criteria, such as having been in medicinal use fr a sufficiently lng time, and hence are cnsidered nt t be harmful under nrmal cnditins f use. Recital 4 f Directive 2004/24/EC prvides that the simplified prcedure f Traditinal Herbal Registratin is nly available where n marketing authrisatin can be btained fr the prduct (pursuant t Directive 2001/83/EC) because f a lack f sufficient scientific literature demnstrating a well-established medicinal use with recgnised efficacy and an acceptable level f safety. Marketing Authrisatin There is a general requirement under Article 6(1) f Directive 2001/83/EC (as amended), that a medicinal prduct must have a Marketing Authrisatin befre it can be placed n the market f a Member State, r be distributed by way f whlesale dealing in the UK. N medicinal prduct may be placed n the market f a Member State unless a marketing authrizatin has been issued by the cmpetent authrities f that Member State in accrdance with this Directive Fr the purpses f this Directive, a medicinal prduct relates t substances (r cmbinatin f substances) which are presented as being capable f preventing disease in human beings r having an effect n the physilgical functins f human beings (Article 1 f Directive 2001/83/EC (as amended)). Medicinal prduct: (a) Any substance r cmbinatin f substances presented as having prperties fr treating r preventing disease in human beings; r (b) Any substance r cmbinatin f substances which may be used in r administered t human beings either with a view t restring, crrecting r 3 P a g e

4 mdifying physilgical functins by exerting a pharmaclgical, immunlgical r metablic actin, r t making a medical diagnsis. Applicatins fr marketing authrisatin f a herbal medicinal prduct must be accmpanied by extensive supprting data, including results f physic-chemical, bilgical r micrbilgical tests, pharmaclgical tests, txiclgical tests and clinical trials, in rder t prve its safety, quality and efficacy. Where yu can prve that there is sufficient scientific literature t demnstrate a wellestablished medicinal use with recgnised efficacy and an acceptable level f safety, then yu may nt be required t prvide the results f pre-clinical tests r clinical trials. The Directive 2004/24/EC states that where the cmpetent authrities judge that a medicine fulfils the criteria fr a Marketing Authrisatin, they shuld nt grant a Traditinal Herbal Registratin (Article 16a(3) Directive 2001/83). in cases where the cmpetent authrities judge that a traditinal herbal medicinal prduct fulfills the criteria fr authrisatin in accrdance with Article 6 the prvisins f this chapter shall nt apply. Use fr 15 years within the Cmmunity Evidence must be prduced t the Medicines and Healthcare Prducts Regulatry Agency ( MHRA ) t shw that a traditinal herbal medicinal prduct, r a crrespnding prduct, has been in medicinal use thrughut a 30 year perid preceding the date f applicatin, including at least 15 years within the Cmmunity (Article 16c(1)(c) f Directive 2001/83/EC (as amended)). (c) bibligraphical r expert evidence t the effect that the medicinal prduct in questin, r a crrespnding prduct has been in medicinal use thrughut a perid f at least 30 years preceding the date f the applicatin, including at least 15 years within the Cmmunity. At the request f the Member State where the applicatin fr traditinal-use registratin has been submitted, the Cmmittee fr Herbal Medicinal Prducts shall draw up an pinin n the adequacy f the evidence f the lng-standing use f the prduct, r f the crrespnding prduct. The Member State shall submit relevant dcumentatin supprting the referral; Article 16c(2) Directive 2001/83/EC (as amended) describes a crrespnding prduct as A crrespnding prduct, as referred t in paragraph 1(c), is characterised by having the same active ingredients, irrespective f the excipients used, the same r similar intended purpse, equivalent strength and pslgy and the same r similar rute f administratin as the medicinal prduct applied fr. Qualified Persn 4 P a g e

5 Any manufacturer hlding a traditinal herbal registratin and manufacturing a traditinal herbal medicinal prduct r a medicinal herbal prduct under a marketing authrisatin must hld a manufacturer s/imprter s authrisatin ( MIA ). Under Eurpean legislatin, the services f at least ne qualified persn must be permanently and cntinuusly at the dispsal f the hlder f a MIA, wh wuld take respnsibility fr the quality f the prducts manufactured at the site where manufactured. The qualified persn must be named n the MIA. The qualified persn des nt have t be a full time emplyee; he r she culd be a cntractr. The main pint is t have a technical agreement between the manufacturer and the qualified persn setting ut the cntractual respnsibilities f the qualified persn. The duties f a qualified persn include: Gd Manufacturing Practice ( GMP ) are fllwed; Adhering t the terms f the traditinal herbal registratin r the marketing authrisatin; Ensuring validatin f manufacturing and testing prcesses; All necessary quality cntrl checks and tests have been cnducted; Ensuring all imprted prducts meet the legal requirements; Ensuring the testing f all prducts imprted frm utside the Eurpean Ecnmic Area ( EEA ) are tested within the EEA t meet the requirements f traditinal herbal registratin r the marketing authrisatin; Each batch is certified/recrded that the requirements f traditinal herbal registratin r the marketing authrisatin are met; Maintaining recrd and ensuring entries are recrded as sn as practicable after each batch has been manufactured and befre the batch is released fr sale. A qualified persn must be resident within the UK. Respnsible Persn The hlder f a whlesale dealer s licence must have a respnsible persn in accrdance with Article 79(b) f Directive 2001/83/EC (as amended). The 5 P a g e

6 Respnsible persn is respnsible fr safeguarding prducts against ptential hazards arising frm pr distributin practice. The respnsible persn is respnsible fr the fllwing: T safeguard prduct users against ptential hazards arising frm pr distributin practices; T ensure that the cnditins f the whlesale dealer s licence are met; Cmpliance with the guidelines f Gd Distributin Practice. A respnsible persn must be resident within the UK. MHRA Guidelines Accrding t the MHRA Guidelines, fr sme herbal medicines there is sufficient evidence in the public dmain fr an applicant t be able t btain a Marketing Authrisatin under the prvisins fr prducts cntaining active substances with 'well established' use by referring t apprpriate scientific literature. Where this is the case the MHRA will nt grant a traditinal use applicatin but will instead ask the applicant t apply fr a Marketing Authrisatin. Based n the MHRA's experience it is likely that this wuld apply in nly a minrity f cases. The MHRA will nt take the view that a prduct ught t fllw the 'well established' rute t a Marketing Authrisatin simply because the medicine cntains a particular herbal ingredient. It may well be that there are sme herbal medicines that have several accepted indicatins, f which ne might be apprpriate fr a Marketing Authrisatin under the 'well established use' prvisins while anther is suitable fr traditinal use registratin. Likewise, it may be that the 'well established use' prvisins are applicable t a range f prducts that use a particular herbal ingredient. Hwever, traditinal use might be applicable where that ingredient is used in cmbinatin with ther active herbal ingredients, particularly fr ther therapeutic indicatins. Such cmbinatins wuld need t satisfy the requirements fr traditinal use registratin including that the efficacy is plausible - based n lng use and experience. There have been sme differences f interpretatin f the 'well established' prvisins between regulatry authrities in different EU Member States. Advice given in ther EU Member States will nt necessarily be applicable in the UK and vice versa. Ptential Grunds fr Revcatin f a Traditinal Herbal Registratin The fllwing are ptential grunds upn which Cmpany A may challenge the traditinal herbal registratin fr certain prducts f Cmpany B. Supprting evidence wuld be required t substantiate the assertins by Cmpany A. 6 P a g e

7 The prducts that have been granted a traditinal herbal registratin, are nt traditinal herbal medicinal prducts and the traditinal herbal registratin f Cmpany B ught t be revked n the fllwing grunds:- The prducts upn which Cmpany B has based its applicatin fr the traditinal herbal registratin, were develped as part f a pharmaceutical prcess using herbal ingredients; Only Cmpany A wns the rights t the prcess (knw-hw); The prduct wned by Cmpany A with identical/similar cmpsitin t the prducts wned by Cmpany B has been n sale in Eurpe fr less than 15 years; There is a questin mark ver the safety f the prducts wned by Cmpany B; The prducts wned by Cmpany B require a Marketing Authrisatin in rder fr Cmpany B t sell these prducts in the UK and the rest f the Eurpean Unin; Marketing Authrisatins already exist fr an identical (if nt, similar) prduct wned by Cmpany A. What is a brderline prduct? Article 1 f Directive 2001/83/EC (as amended) as amended defines a medicinal prduct as: Any substance r cmbinatin f substances presented as having prperties fr treating r preventing disease in human beings; Any substance r cmbinatin f substances which may be used in r administered t human beings either with a view t restring, crrecting r mdifying physilgical functins by exerting a pharmaclgical, immunlgical r metablic actin, r t making a medical diagnsis. There are sme prducts where it is nt s easy t distinguish a medicine frm, fr example, csmetics r fd supplements. These are knwn as brderline prducts. A prduct which is fr use nly as a tiletry, disinfectant, fd r beverage is nt nrmally regarded as a medicinal prduct, and wuld nt require a marketing authrisatin t be sld in the UK. Dietary supplements cntaining vitamins, amin acids r minerals, are generally subject t fd safety and fd labelling legislatin rather than medicines cntrl. 7 P a g e

8 In the event that a fd and/r csmetic cntain a pharmaclgically active substance r make medicinal claims (claims t treat r prevent disease, r t interfere with the nrmal peratin f a physilgical functin f the human bdy are regarded as medicinal). Cnclusin Cmpanies manufacturing and/r distributing herbal medicines must ensure cmpliance with the law. RT COOPERS, This Briefing Nte des nt prvide a cmprehensive r cmplete statement f the law relating t the issues discussed nr des it cnstitute legal advice. It is intended nly t highlight general issues. Specialist legal advice shuld always be sught in relatin t particular circumstances. The authr is Dr Rsanna Cper f RT Cpers Slicitrs. She is an expert in regulatry law, in particular, herbal medicines. Dr Cper is a chartered chemist and a fellw f the Ryal Sciety f Chemistry. She may be cntacted n +44 (0) r by enquiries@rtcpersslicitrs.cm. Fr mre infrmatin n the services prvided by RT Cpers n csmetic law, visit 8 P a g e

This standard operating procedure applies to stop smoking services provided by North 51.

This standard operating procedure applies to stop smoking services provided by North 51. Authr Name/Title Melanie McIlvar, Bid Develpment Manager Authr Signature Date: 4 th September 2017 Apprver Name/Title Jasn Shelley, Grup Directr f QA/RA Apprver Signature Date: 4 th September 2017 Issue

More information

Potential Grounds for Revocation of a Traditional Herbal Registration

Potential Grounds for Revocation of a Traditional Herbal Registration Potential Grounds for Revocation of a Traditional Herbal Registration By Dr Rosanna Cooper In this article we will be exploring the potential grounds for revocation of the Traditional Herbal Registration

More information

FDA Dietary Supplement cgmp

FDA Dietary Supplement cgmp FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes

More information

The Cannabis Act and Regulations

The Cannabis Act and Regulations The and Regulatins OVERVIEW The and Regulatins cme int frce n Octber 17, 2018 and replaces the Access t Cannabis fr Medical Purpses Regulatins (ACMPR), and any mentin f Cannabis and Marihuana in the Narctics

More information

SUMMARY THE EUROPEAN COMMUNITY STRATEGY

SUMMARY THE EUROPEAN COMMUNITY STRATEGY SUMMARY THE EUROPEAN COMMUNITY STRATEGY FOR THE PHASEOUT OF CFCS IN MDIS 1. The Eurpean Cmmunity s transitin strategy fr the phaseut f CFCs in metered-dse inhalers (MDIs) was submitted t the Parties t

More information

DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004

DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. of 31 March 2004 30.4.2004 Official Journal of the European Union L 136/85 DIRECTIVE 2004/24/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 31 March 2004 amending, as regards traditional herbal medicinal products,

More information

Cancer Association of South Africa (CANSA)

Cancer Association of South Africa (CANSA) Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.

More information

A fake medicine that passes itself off as a real, authorised medicine. (1)

A fake medicine that passes itself off as a real, authorised medicine. (1) Falsified medicines Index 1 Intrductin 2 Types f falsified medicines 3 Eurpean regulatin n falsified medicines 4 Risks f falsified medicines 5 Buying medicine nline safely 6 References 7 Further resurces

More information

PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS

PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS INTRODUCTION This ntice prvides an verview f the parental special educatin rights, smetimes called prcedural safeguards

More information

Call for evidence on the use of skin sensitisers, skin irritants and corrosive substances in textile and leather articles, hides and furs

Call for evidence on the use of skin sensitisers, skin irritants and corrosive substances in textile and leather articles, hides and furs Call fr evidence n the use f skin sensitisers, skin irritants and crrsive substances in textile and leather articles, hides and furs Backgrund dcument Backgrund Prductin and prcessing f textile and leather

More information

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,

More information

Corporate Governance Code for Funds: What Will it Mean?

Corporate Governance Code for Funds: What Will it Mean? Crprate Gvernance Cde fr Funds: What Will it Mean? The Irish Funds Industry Assciatin has circulated a draft Vluntary Crprate Gvernance Cde fr the Funds Industry in Ireland. 1. Backgrund On 13 June 2011,

More information

Completing the NPA online Patient Safety Incident Report form: 2016

Completing the NPA online Patient Safety Incident Report form: 2016 Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject

More information

ACMPR - Access to Cannabis for Medical Purposes Regulations Part 1 Commercial Production

ACMPR - Access to Cannabis for Medical Purposes Regulations Part 1 Commercial Production - Access t Cannabis fr Medical Purpses Regulatins Part 1 Cmmercial Prductin September 2017 OVERVIEW Yu must cmply with regulatins t supply medical cannabis as f August 24, 2016 There are fur parts t the

More information

Related Policies None

Related Policies None Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER

More information

SECTION O. MEDICATIONS

SECTION O. MEDICATIONS SECTION O. MEDICATIONS 1. NUMBER OF MEDICA TIONS (Recrd the number f different medicatins used in the last 7 days; enter "0" if nne used) O1. Number f Medicatins (7-day lk back) Intent: Prcess: Cding:

More information

DISTRIBUTION: ORGANIZATION WIDE APPROVED BY: VP COMPLIANCE

DISTRIBUTION: ORGANIZATION WIDE APPROVED BY: VP COMPLIANCE LAST REVISED: Page 1 f 5 POLICY CarePint Health (Baynne Medical Center, Christ Hspital, Hbken University Medical Center, CarePint Health Medical Grup, Garden State Healthcare Assciates, CarePint Health

More information

Year 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:

Year 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher: Year 10 Fd Technlgy Assessment Task 1: Fds fr Special Needs Name: Teacher: Due Date: Term 2, Week 1 Type f Task: Design Task Planning Fd Requirements Cllectin f Assessment: Submit in Class Assessment Plicy:

More information

Assessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams

Assessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.

More information

Code of employment practice on infant feeding

Code of employment practice on infant feeding Cde f emplyment practice n infant feeding An Emplyer s guide t: Sectin 69Y f the Emplyment Relatins Act 2000 Frewrd As Minister f Labur, I am pleased t publish the Cde f Emplyment Practice n Infant Feeding.

More information

Immunisation and Disease Prevention Policy

Immunisation and Disease Prevention Policy Immunisatin and Disease Preventin Plicy Quality Area 2: Children s Health and Safety 2.1 Each child s health is prmted 2.1.4 Steps are taken t cntrl the spread f infectius diseases and t manage injuries

More information

Indirect Sales. Proof Policy. Indirect Channel. Version May Author: Credit Risk & Fraud. External version

Indirect Sales. Proof Policy. Indirect Channel. Version May Author: Credit Risk & Fraud. External version Prf Plicy Indirect Channel Versin 12 7 May 2015 Authr: Credit Risk & Fraud External versin 1 Table f Cntents Intrductin... 3 Distance Selling... 4 Face t Face Selling... 10 Additinal Prfs Plicy Infrmatin...

More information

FOR RESTRICTED AOs DIPLOMA IN POLICING ASSESSMENT UNITS Banked. D/507/3718 Interview suspects in relation to priority and volume investigations

FOR RESTRICTED AOs DIPLOMA IN POLICING ASSESSMENT UNITS Banked. D/507/3718 Interview suspects in relation to priority and volume investigations Title: D/507/3718 Interview suspects in relatin t pririty and vlume investigatins Level: 4 Credit Value: 6 GLH: 20 Learning Outcmes The learner will: 1. understand the principles f interviewing suspects

More information

Assessment criteria for Primary Health Disciplines Eligibility for Recognition as Credentialled Diabetes Educator. December 2015 ADEA

Assessment criteria for Primary Health Disciplines Eligibility for Recognition as Credentialled Diabetes Educator. December 2015 ADEA Assessment criteria fr Primary Health Disciplines Eligibility fr Recgnitin as Credentialled Diabetes Educatr December 2015 ADEA ASSESSMENT CRITERIA FOR PRIMARY HEALTH DICIPLINES ELIGIBILITY FOR RECOGNITION

More information

Annex E Terms of Reference: Therapeutic use

Annex E Terms of Reference: Therapeutic use Annex E Terms f Reference: Therapeutic use The purpse f the pre-review reprt is t synthesize existing scientific evidence abut the therapeutic use and ptential fr dependence and abuse f cannabisrelated

More information

Action plan: serialisation of Nordic packages focus on Product Codes

Action plan: serialisation of Nordic packages focus on Product Codes 19.6.2017, versin 5 Actin plan: serialisatin f Nrdic packages fcus n Prduct Cdes The aim f this dcument is t help pharma cmpanies t prepare fr prduct cde changes and t be able t maintain prduct cdes in

More information

Methadone Maintenance Treatment for Opioid Dependence

Methadone Maintenance Treatment for Opioid Dependence POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin

More information

Commissioning Policy: South Warwickshire CCG (SWCCG)

Commissioning Policy: South Warwickshire CCG (SWCCG) Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding

More information

EUROPEAN MEDICINES AGENCY DECISION. of 14 October 2008

EUROPEAN MEDICINES AGENCY DECISION. of 14 October 2008 Eurpean Medicines Agency Dc. Ref. EMEA/522876/2008 P/84/2008 EUROPEAN MEDICINES AGENCY DECISION f 14 Octber 2008 n the applicatin fr agreement f a Paediatric Investigatin Plan fr valsartan (Divan) (EMEA-000005-PIP01-07)

More information

S.K.J Construction Ltd Groundwork & Civil Engineering

S.K.J Construction Ltd Groundwork & Civil Engineering S.K.J Cnstructin Ltd Grundwrk & Civil Engineering SUBSTANCE MISUSE POLICY 1 2 SUBSTANCE MISUSE POLICY 1 INTRODUCTION Plicy Aims Frm the viewpint f health and safety at wrk, SKJ Cnstructin Ltd (the Cmpany)

More information

OAC 310:681 8/7/2018. Subchapter 1. General Provisions. Subchapter 1. General Provisions. Medical Marijuana Control Program. 310:

OAC 310:681 8/7/2018. Subchapter 1. General Provisions. Subchapter 1. General Provisions. Medical Marijuana Control Program. 310: OAC 310:681 Medical Marijuana Cntrl Prgram Subchapter 1. General Prvisins 310:681-1-1. Purpse Regulatry agency: Oklahma Medical Marijuana Authrity, divisin f Oklahma State Department f Health 310:681-1-2.

More information

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED

More information

The ECG app is not intended for use by people under 22 years old.

The ECG app is not intended for use by people under 22 years old. ECG App Instructins fr Use Apple Inc. One Apple Park Way Cupertin, CA 95014 www.apple.cm INDICATIONS FOR USE The ECG app is a sftware-nly mbile medical applicatin intended fr use with the Apple Watch t

More information

Meaningful Use Roadmap Stage Edition Eligible Hospitals

Meaningful Use Roadmap Stage Edition Eligible Hospitals Meaningful Use Radmap Stage 1-2011 Editin Eligible Hspitals CPSI is dedicated t making yur transitin t Meaningful Use as seamless as pssible. Therefre, we have cme up with a radmap t assist yu in implementing

More information

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select

More information

2016 CWA Political Action Fund Administrative Procedures Checklist

2016 CWA Political Action Fund Administrative Procedures Checklist 2016 CWA Plitical Actin Fund Administrative Prcedures Checklist 1. Dates f Prgram The 2016 CWA Plitical Actin Fund (federal plitical actin cmmittee- CWA-COPE PCC) Prgram will be cnducted n a calendar year

More information

A catalogue of criteria to objectify the harm-benefit analysis according to Austrian legislation

A catalogue of criteria to objectify the harm-benefit analysis according to Austrian legislation LINZ 2013 18th Eurpean Cngress n Alternatives t Animal Testing EUSAAT 2013 15th Annual Cngress f EUSAAT 15 18 September 2013, University f Linz, Austria A catalgue f criteria t bjectify the harm-benefit

More information

(Please text me on once you have submitted your request online and the cell number you used)

(Please text me on once you have submitted your request online and the cell number you used) Dear Thank yu fr yur email, nted. Belw steps n hw t register as a service prvider. Please nte that nce yu have requested t becme a service prvider, yu need t sms/what s up me n 0826392585, in rder t activate

More information

NATIONAL WEEK OF DEAF PEOPLE 19 th 25 th October 2013 EVENT QUIDELINES. Equality for Deaf People

NATIONAL WEEK OF DEAF PEOPLE 19 th 25 th October 2013 EVENT QUIDELINES. Equality for Deaf People NATIONAL WEEK OF DEAF PEOPLE 19 th 25 th Octber 2013 EVENT QUIDELINES Equality fr Deaf Peple NATIONAL WEEK OF DEAF PEOPLE EVENT GUIDELINES 2013 TABLE OF CONTENTS What is Natinal Week f Deaf Peple? 3 Type

More information

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria

Benefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health

More information

For personal use only

For personal use only Fr persnal use nly ASX / MEDIA RELEASE FOR IMMEDIATE RELEASE 10 May 2013 CROWN RECEIVES NSW GAMING REGULATORY APPROVALS MELBOURNE: Crwn Limited (ASX: CWN) annunced tday that it has received written advice

More information

Human papillomavirus (HPV) refers to a group of more than 150 related viruses.

Human papillomavirus (HPV) refers to a group of more than 150 related viruses. HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between

More information

Annual Principal Investigator Worksheet About Local Context

Annual Principal Investigator Worksheet About Local Context Cmpleting the NCI CIRB Annual Principal Investigatr Wrksheet Abut Lcal Cntext and the Study-Specific Wrksheet Abut Lcal Cntext at the University f Iwa All investigatrs cnducting research with the Natinal

More information

Annex III. Amendments to relevant sections of the Product Information

Annex III. Amendments to relevant sections of the Product Information Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t

More information

Recommendations for Risk Management at Swine Exhibitions and for Show Pigs August 2012

Recommendations for Risk Management at Swine Exhibitions and for Show Pigs August 2012 Recmmendatins fr Risk Management at Swine Exhibitins and fr Shw Pigs August 2012 Backgrund: The Natinal Prk Bard facilitated in develping this dcument. These recmmendatins were develped by a wrking grup

More information

Pain relief after surgery

Pain relief after surgery Pain relief after surgery Imprtant infrmatin fr patients www.mchft.nhs.uk We care because yu matter This leaflet is designed t help yu cntrl any pain yu may have at hme fllwing yur peratin. Please read

More information

EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS

EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS 1 SECTION 1 INTRODUCTION: EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS The Nature Of Assessment The Definitin Of Assessment The Difference Between Testing, Measurement And Evaluatin Characteristics

More information

SUFFOLK COUNTY COUNCIL. Anti- Social Behaviour Act Penalty Notice. Code of conduct

SUFFOLK COUNTY COUNCIL. Anti- Social Behaviour Act Penalty Notice. Code of conduct SUFFOLK COUNTY COUNCIL Anti- Scial Behaviur Act 2003 Penalty Ntice Cde f cnduct SCC Penalty Ntice Cde f Cnduct & Administrative Guidance: revised August 2014 1 Cntents 1. Legal Basis 2. Purpse f the Penalty

More information

UNIT 6. DEVELOPING THREAT/HAZARD-SPECIFIC ANNEXES

UNIT 6. DEVELOPING THREAT/HAZARD-SPECIFIC ANNEXES UNIT 6. DEVELOPING THREAT/HAZARD-SPECIFIC ANNEXES This page intentinally left blank. UNIT INTRODUCTION Visual 6.1 This unit presents infrmatin n annexes that shuld be included in a schl emergency peratins

More information

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.

More information

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...

More information

ARLA FOOD FOR HEALTH 4 th ANNUAL CALL FOR EXPRESSIONS OF INTEREST

ARLA FOOD FOR HEALTH 4 th ANNUAL CALL FOR EXPRESSIONS OF INTEREST ARLA FOOD FOR HEALTH 4 th ANNUAL CALL FOR EXPRESSIONS OF INTEREST 7 th July 2017 Cntent 1 Intrductin 2 Tpics fr EOI in the 4 th call 3 The applicatin prcess and imprtant dates 4 Guideline fr EOIs Deadline

More information

STANDARD FOR POMEGRANATE (CODEX STAN )

STANDARD FOR POMEGRANATE (CODEX STAN ) CODEX STAN 310-2013 Page 1 f 5 1. DEFINITION OF PRODUCE STANDARD FOR POMEGRANATE (CODEX STAN 310-2013) This Standard applies t fruits f cmmercial varieties f pmegranates grwn frm Punica granatum L., f

More information

Section 6 Students School District No. 71 (Comox Valley)

Section 6 Students School District No. 71 (Comox Valley) Sectin 6 Students Schl District N. 71 (Cmx Valley) Administrative Prcedure 6011 MR2 Allergies and Anaphylaxis 1. Intrductin The Bard f Educatin expects schls t reasnably accmmdate students with medically

More information

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009 CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral

More information

IMMIGRATION Canada. Temporary Resident Visa. Los Angeles and New York City Visa Office Instructions. Table of Contents IMM 5876 E ( )

IMMIGRATION Canada. Temporary Resident Visa. Los Angeles and New York City Visa Office Instructions. Table of Contents IMM 5876 E ( ) IMMIGRATION Canada Table f Cntents Dcument Checklist Temprary resident visa Temprary Resident Visa Ls Angeles and New Yrk City Visa Office Instructins This applicatin is made available free by Immigratin,

More information

Building Code 101 OWMC November 20, Ministry of Municipal Affairs and Housing

Building Code 101 OWMC November 20, Ministry of Municipal Affairs and Housing Building Cde 101 OWMC Nvember 20, 2015 Ministry f Municipal Affairs and Husing Disclaimer These slides are prvided by the Ministry f Municipal Affairs and Husing fr cnvenience nly The slides shuld nt be

More information

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018) Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages

More information

2017 Optum, Inc. All rights reserved BH1124_112017

2017 Optum, Inc. All rights reserved BH1124_112017 1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases

More information

CHEAC Summary. BMCR Medical Cannabis Regulations. Distribution, Transportation and Dispensaries

CHEAC Summary. BMCR Medical Cannabis Regulations. Distribution, Transportation and Dispensaries CHEAC Summary BMCR Medical Cannabis Regulatins Distributin, Transprtatin and Dispensaries The Bureau f Medical Cannabis Regulatin (BMCR) prpsed regulatins fcus n the applicatin, licensing, and perating

More information

Independent Charitable Patient Assistance Program (IPAP) Code of Ethics

Independent Charitable Patient Assistance Program (IPAP) Code of Ethics Independent Charitable Patient Assistance Prgram (IPAP) Cde f Ethics Independent charitable patient assistance prgrams (IPAPs) fcus n the needs f patients wh are insured, meet certain financial limitatin

More information

Injury, Incident & Illness Procedure

Injury, Incident & Illness Procedure Injury, Incident & Illness Prcedure Injury / Incident Includes any child, adult, r emplyee injured n site. A first aid kit will be available at all times. It will be maintained in accrdance with criterin

More information

Imaging tests allow the cancer care team to check for cancer and other problems inside the body.

Imaging tests allow the cancer care team to check for cancer and other problems inside the body. IMAGING TESTS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between yu

More information

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting

More information

Swindon Joint Strategic Needs Assessment Bulletin

Swindon Joint Strategic Needs Assessment Bulletin Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical

More information

A Unified Approach to Conflict Mineral Compliance for the Tungsten Industry. The Westin, Sydney, 23 September 2013

A Unified Approach to Conflict Mineral Compliance for the Tungsten Industry. The Westin, Sydney, 23 September 2013 A Unified Apprach t Cnflict Mineral Cmpliance fr the Tungsten Industry The Westin, Sydney, 23 September 2013 Backgrund Cmpliance f public US dwnstream tungsten users with the reprting requirements f the

More information

Cardiac Rehabilitation Services

Cardiac Rehabilitation Services Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin

More information

ALCAT FREQUENTLY ASKED QUESTIONS

ALCAT FREQUENTLY ASKED QUESTIONS 1. Is fasting required befre taking the Alcat Test? N. It is recmmended t drink water and t avid stimulants like caffeine prir t the test. 2. With regard t testing children, must a child be a certain age

More information

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion

Intravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment

More information

Hospital Preparedness Checklist

Hospital Preparedness Checklist Hspital Preparedness Checklist http://pandemicflu.gv Preparedness Subject 1. Structure fr planning and decisin making An internal, multidisciplinary planning cmmittee fr influenza preparedness has been

More information

Food Stamp Program Pandemic Flu Planning

Food Stamp Program Pandemic Flu Planning 06/27/07 SUBJECT: TO: Fd Stamp Prgram Pandemic Flu Planning All Reginal Administratrs Fd and Nutritin Service The Fd and Nutritin Service (FNS) recently devised guidelines fr the peratin f key nutritin

More information

MGPR Training Courses Guide

MGPR Training Courses Guide MGPR Training Curses Guide fiscal cde 92107050921 1. Descriptin The training prgram supprted by MGPR is prpsed by a grup f excellent mentrs/educatrs, accmplished in Pesticides Management and Analysis,

More information

Frontier School of Innovation District Wellness Policy

Frontier School of Innovation District Wellness Policy Frntier Schl f Innvatin 6700 Crprate dr. Suite 150 Phne: 816-363-1907 http://www.kcfsi.rg/ Frntier Schl f Innvatin District Wellness Plicy The Bard prmtes healthy schls, by supprting wellness, gd nutritin,

More information

British Sign Language (BSL) Plan October 2018 Scottish Charity Regulator

British Sign Language (BSL) Plan October 2018 Scottish Charity Regulator British Sign Language (BSL) Plan 2018-2024 Octber 2018 Scttish Charity Regulatr Cntents Sectin 1: Intrductin and cntext 1.1 Intrductin 1.2 Our wrk and what we d Sectin 2: Our BSL Plan 2.1 Scttish Public

More information

Specifically, on page 12 of the current evicore draft, we find the statement:

Specifically, on page 12 of the current evicore draft, we find the statement: Octber 23, 2016 evicre Healthcare Attn: Dr Greg Allen 400 Buckwalter Place Bulevard Blufftn, SC 29910 RE: evicre Draft Onclgy Imaging Guidelines, v 19.0 Gentlepersns: Prstate Cancer Internatinal is a nt-fr-prfit

More information

1100 Marie Mount Hall College Park, Maryland Tel: (301) Fax: (301)

1100 Marie Mount Hall College Park, Maryland Tel: (301) Fax: (301) UNIVERSITY SENATE 1100 Marie Munt Hall Cllege Park, Maryland 20742-7541 Tel: (301) 405-5805 Fax: (301) 405-5749 http://www.senate.umd.edu March 31, 2017 Jrdan Gdman Chair, University Senate 2208G Physical

More information

TO: Mayor & Council DATE: March 8, The Planning & Development Department and the Legal Services Division recommend that Council:

TO: Mayor & Council DATE: March 8, The Planning & Development Department and the Legal Services Division recommend that Council: CORPORATE REPORT NO: R049 COUNCIL DATE: March 12, 2018 REGULAR COUNCIL TO: Mayr & Cuncil DATE: March 8, 2018 FROM: SUBJECT: General Manager, Planning & Develpment City Slicitr, Legal Services Cannabis

More information

The Mental Capacity Act 2005; a short guide for the carers and relatives of those who may need support. Ian Burgess MCA Lead 13 February 2017

The Mental Capacity Act 2005; a short guide for the carers and relatives of those who may need support. Ian Burgess MCA Lead 13 February 2017 The Mental Capacity Act 2005; a shrt guide fr the carers and relatives f thse wh may need supprt Ian Burgess MCA Lead 13 February 2017 Agenda Overview f the MCA The 5 Principles and the legal definitin

More information

Percutaneous Nephrolithotomy (PCNL)

Percutaneous Nephrolithotomy (PCNL) Percutaneus Nephrlithtmy (PCNL) What is a percutaneus nephrlithtmy? is the mst effective f the cmmnly perfrmed prcedures fr kidney stnes. It is the best prcedure fr large and cmplex stnes. T perfrm this

More information

Dental Benefits. Under the TeamstersCare Plan, you and your eligible dependents have three basic options when you need dental care.

Dental Benefits. Under the TeamstersCare Plan, you and your eligible dependents have three basic options when you need dental care. Dental Benefits Under the TeamstersCare Plan, yu and yur eligible dependents have three basic ptins when yu need dental care. Optin #1: TeamstersCare Dentists. Yu can use ur in-huse Charlestwn, Chelmsfrd,

More information

You may have a higher risk of bleeding if you take warfarin sodium tablets and:

You may have a higher risk of bleeding if you take warfarin sodium tablets and: MEDICATION GUIDE Warfarin (WAR-far-in) Sdium (SO-dee-um) Tablets USP The 7.5 mg tablets cntain FD&C Yellw N. 5 (tartrazine), which may cause allergic-type reactins (including brnchial asthma) in certain

More information

2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE

2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizations, Clinical Cascade Breakout Session TB/HIV EXERCISE 2017 PEPFAR Data and Systems Applied Learning Summit Day 2: MER Analytics/Available Visualizatins, Clinical Cascade Breakut Sessin TB/HIV EXERCISE Created by the ICPI TB/HIV Wrkstream Abut this Handut

More information

WHAT IS HEAD AND NECK CANCER FACT SHEET

WHAT IS HEAD AND NECK CANCER FACT SHEET WHAT IS HEAD AND NECK CANCER FACT SHEET This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice

More information

Lee County Florida Income Guideline Chart

Lee County Florida Income Guideline Chart NEIGHBORHOOD STABILIZATION PROGRAM OF LEE COUNTY BUYER-RELATED QUESTIONS 1. Why is NSP beneficial t yur buyers? Three key advantages make the NSP Prgram especially attractive t eligible buyers: 1) Investrs

More information

How to become an AME Online

How to become an AME Online Hw t becme an AME Online 1. Check that yu meet the minimum technical requirements in rder t use the AME Online system: Operating System: Windws Vista (Service Pack 2) Windws 7 Windws 8, 8.1 Windws 10 Please

More information

Limitations and Exclusions (What is Not Covered)

Limitations and Exclusions (What is Not Covered) Clrad Dental Family + Pediatric Plan Exclusins and Limitatins Limitatins and Exclusins (What is Nt Cvered) Excluded Services: Age 19 and lder Cvered Expenses d nt include expenses incurred fr: prcedures

More information

TABLE OF CONTENTS Glossary of terms Code Pad Diagram 3. Understanding the Code Pad lights.4.

TABLE OF CONTENTS Glossary of terms Code Pad Diagram 3. Understanding the Code Pad lights.4. TABLE OF CONTENTS... Glssary f terms 2... Cde Pad Diagram 3 Understanding the Cde Pad lights.4 Cde Pad tnes 5 Fully arming the system - ON MODE 6 Fully arming the system - Quick Arm MODE 6 Partially arming

More information

Training module 1: Summary

Training module 1: Summary Draft (Step 2) guideline ICH E9(R1) Estimands and Sensitivity Analysis in Clinical Trials Training mdule 1: Summary Addendum t ICH E9 Statistical Principles fr Clinical Trials ICH E9(R1) Expert Wrking

More information

DRAFT Policy for the Management of Ear Wax

DRAFT Policy for the Management of Ear Wax Clinical Cmmissining Grup (CCG) Treatment Plicy NHS Birmingham and Slihull Clinical Cmmissining Grup NHS Sandwell and West Birmingham Clinical Cmmissining Grup DRAFT Plicy fr the Management f Ear Wax 1

More information

Interpretation. Historical enquiry religious diversity

Interpretation. Historical enquiry religious diversity Name: Year 8 Histry Prject 3: D The Cmmnwealth Games Still Matter In The 21 st Century? Mdule: Date Set: Deadline: Descriptin f the task: The prject is split int three separate parts: The prject is split

More information

PSYCHOSEXUAL ASSESSMENTS for Children and Adolescents with Problematic Sexual Behavior. Who is qualified to conduct a psychosexual evaluation?

PSYCHOSEXUAL ASSESSMENTS for Children and Adolescents with Problematic Sexual Behavior. Who is qualified to conduct a psychosexual evaluation? PSYCHOSEXUAL ASSESSMENTS fr Children and Adlescents with Prblematic Sexual Behavir When a child r adlescent is suspected r bserved t have engaged in what may be sexually inapprpriate r sexually aggressive

More information

Coding. Training Guide

Coding. Training Guide Cding (Specialty Hspital) Visin 4.3 (January 2013) Training Guide SurceMedical VisinSH Cding Learning Center f Excellence Last change made: January 2013 2013 Surce Medical Slutins, Inc. All Rights Reserved.

More information

QP Energy Services LLC Hearing Conservation Program HSE Manual Section 7 Effective Date: 5/30/15 Revision #:

QP Energy Services LLC Hearing Conservation Program HSE Manual Section 7 Effective Date: 5/30/15 Revision #: QP Energy Services LLC Hearing Cnservatin Prgram HSE Manual Sectin 7 Effective Date: 5/30/15 Revisin #: Prepared by: James Aregd Date: 5/30/15 Apprved by: James Aregd Date: 5/30/15 Page 1 f 8 Cntents Sectin

More information

Programme of Learning. Physical Education. Key Stage 4 Year 10 BTEC Sport

Programme of Learning. Physical Education. Key Stage 4 Year 10 BTEC Sport Prgramme f Learning Physical Educatin Key Stage 4 Year 10 BTEC Sprt BTEC Sprt Level 2 Unit 1Fitness fr Sprt and Exercise... 2 Learning aim A: Knw abut the cmpnents f fitness and the principles f training...

More information

1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT

1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION A: GUIDELINES RELEVANT TO OBSTETRICS AND GYNAECOLOGY 1 STANDARD PROTOCOLS 1.11 INSULIN INFUSION PUMP MANAGEMENT - INPATIENT Authrised by: OGCCU

More information

Patient Name: Address City State Zip Code. H. Phone W. Phone Cell Phone

Patient Name: Address City State Zip Code. H. Phone W. Phone Cell Phone Name yu prefer t g by: Address City State Zip Cde H. Phne W. Phne Cell Phne Email Address: Sex: M F Date f Birth Age Marital Status: M S D W Spuse s Name if Married: Scial Security # Referred by: Persn

More information

LIST YOUR HEALTH CONCERNS BELOW

LIST YOUR HEALTH CONCERNS BELOW Name Date / / Age Male/Female Address City State Zip Phne: Hme Cell_ Date f Birth / / Email Address Fr cnfirming appintments, wuld yu prefer? EMAIL r TEXT CELL PROVIDER IS Occupatin Emplyer s Name Single

More information

Screening Questions to Ask Patients

Screening Questions to Ask Patients Screening Questins t Ask Patients 1. Have yu ever had TB (Tuberculsis)? Yes N 2. Have yu been living with anyne in the past tw years that has been diagnsed with TB? Yes N 3. Have yu ever had a Persistent

More information

NAPPI CODE ALLOCATION POLICY VERSION 2.7

NAPPI CODE ALLOCATION POLICY VERSION 2.7 NAPPI CODE ALLOCATION POLICY VERSION 2.7 Cpyright Ntice: 2003-2017 Cpyright reserved by MediKredit Integrated Healthcare Slutins (Pty) Ltd 10 Kikuyu Rd, Sunninghill, Sandtn, 2157 All rights, title and

More information

Package leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate

Package leaflet: Information for the user. Dacepton 5 mg/ml Solution for infusion Apomorphine hydrochloride hemihydrate Package leaflet: Infrmatin fr the user Daceptn 5 mg/ml Slutin fr infusin Apmrphine hydrchlride hemihydrate Read all f this leaflet carefully befre yu start using this medicine because it cntains imprtant

More information